Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
1999-08-27
2002-11-05
Shah, Mukund J. (Department: 1611)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S293000, C544S258000, C544S279000, C514S259500, C514S258100, C514S252170
Reexamination Certificate
active
06476031
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to treating various disorders associated with enhanced activity of kinase p38-&agr; and/or transforming growth factor beta (TGF-&bgr;). More specifically, it concerns compounds that are related to quinazoline as useful in these methods.
BACKGROUND ART
A large number of chronic and acute conditions have been recognized to be associated with perturbation of the inflammatory response. A large number of cytokines participate in this response, including IL-1, IL-6, IL-8 and TNF. It appears that the activity of these cytokines in the regulation of inflammation rely at least in part on the activation of an enzyme on the cell signaling pathway, a member of the MAP kinase family generally known as p38 and alternatively known as CSBP and RK. This kinase is activated by dual phosphorylation after stimulation by physiochemical stress, treatment with lipopolysaccharides or with proinflammatory cytokines such as IL-I and TNF. Therefore, inhibitors of the kinase activity of p38 are useful antiinflammatory agents.
Transforming growth factor-beta (TGF-&bgr;) denotes a family of proteins, TGF-&bgr;1, TGF-&bgr;2, and TGF-&bgr;3, which are pleiotropic modulators of cell growth and differentiation, embryonic and bone development, extracellular matrix formation, hematopoiesis, immune and inflammatory responses (Roberts and Sporn
Handbook of Experimental Pharmacology
(1990) 95:419-58; Massague et al.
Ann Rev Cell Biol
(1990) 6:597-646). Other members of this superfamily include activin, inhibin, bone morphogenic protein, and Mullerian inhibiting substance. TGF-&bgr; initiates an intracellular signaling pathway leading ultimately to the expression of genes that regulate the cell cycle, control proliferative responses, or relate to extracellular matrix proteins that mediate outside-in cell signaling, cell adhesion, migration and intercellular communication.
Therefore, inhibitors of the TGF-&bgr; intracellular signaling pathway are useful treatments for fibroproliferative diseases. Specifically, fibroproliferative diseases include kidney disorders associated with unregulated TGF-&bgr; activity and excessive fibrosis including glomerulonephritis (GN), such as mesangial proliferative GN, immune GN, and crescentic GN. Other renal conditions include diabetic nephropathy, renal interstitial fibrosis, renal fibrosis in transplant patients receiving cyclosporin, and HIV-associated nephropathy. Collagen vascular disorders include progressive systemic sclerosis, polymyositis, scleroderma, dermatomyositis, eosinophilic fascitis, morphea, or those associated with the occurrence of Raynaud's syndrome. Lung fibroses resulting from excessive TGF-&bgr; activity include adult respiratory distress syndrome, idiopathic pulmonary fibrosis, and interstitial pulmonary fibrosis often associated with autoimmune disorders, such as systemic lupus erythematosus and scleroderma, chemical contact, or allergies. Another autoimmune disorder associated with fibroproliferative characteristics is rheumatoid arthritis.
Eye diseases associated with a fibroproliferative condition include retinal reattachment surgery accompanying proliferative vitreoretinopathy, cataract extraction with intraocular lens implantation, and post glaucoma drainage surgery.
PCT applications WO98/06715, WO98/07425, and WO96/40143, all of which are incorporated herein by reference, describe the relationship of p38 kinase inhibitors with various disease states. As mentioned in these applications, inhibitors of p38 kinase are useful in treating a variety of diseases associated with chronic inflammation. These applications list rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, asthma, adult respiratory distress syndrome, stroke, reperfusion injury, CNS injuries such as neural trauma and ischemia, psoriasis, restenosis, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, bone resorption diseases such as osteoporosis, graft-versus-host reaction, Crohn's Disease, ulcerative colitis including inflammatory bowel disease (IBD) and pyresis.
The above-referenced PCT applications disclose compounds which are p38 kinase inhibitors said to be useful in treating these disease states. These compounds are either imidazoles or are indoles substituted at the 3- or 4-position with a piperazine ring linked through a carboxamide linkage. Additional compounds which are conjugates of piperazines with indoles are described as insecticides in WO97/26252, also incorporated herein by reference.
The compounds of the invention are quinazoline derivatives. Other quinazoline compounds for other uses have been described. U.S. Pat. No. 5,721,237 assigned to Rhone-Poulenc Rorer is directed to methods for selective treatment of cell growth and differentiation characterized by activity of human epidermal growth factor receptor type II using quinazoline substituted only in the 4-position with an aromatic moiety optionally coupled to the quinazoline through a linking moiety. U.S. Pat. No. 4,480,883 describes compounds that exhibit tyrosine kinase inhibition activity wherein the heterocyclic portion of a quinazoline or other fused ring nitrogen-containing aromatic system is substituted only once with an aromatic moiety, again optionally coupled through a linker. U.S. Pat. No. 5,616,582 assigned to Zeneca describes tyrosine kinase inhibitors which are quinazolines linked through an amino group at the 4-position to a substituted or unsubstituted phenyl. These compounds contain no substituents at position 2. U.S. Pat. No. 5,475,001 also assigned to Zeneca describes similar compounds with the same activity. U.S. Pat. No. 5,430,148 assigned to Agouron Pharmaceutical describes antiproliferative substituted quinazolinones and their counterparts wherein the keto group is replaced by a sulfone.
U.S. Pat. No. 5,719,157 to Takeda Chemical Industries describes pharmaceutical compositions for inhibiting bone resorption which include 4-phenyl quinoline derivatives which may further be substituted at the 2-position with an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group.
None of the foregoing patents describes quinazoline derivatives which specifically inhibit p38-&agr; or TGF-&bgr;.
DISCLOSURE OF THE INVENTION
The invention is directed to methods and compounds useful in treating conditions that are characterized by enhanced p38-&agr; activity and/or TGF-&bgr; activity. These conditions include inflammation, proliferative diseases, and certain cardiovascular disorders as further described below.
Compounds of the invention have been found to inhibit p38 kinase, the &agr;-isoform in particular, and/or TGF-&bgr; and are thus useful in treating diseases mediated by these activities. The compounds of the invention are of the formula
or the pharmaceutically acceptable salts thereof
wherein R
3
is a noninterfering substituent;
each Z is CR
2
or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N;
each R
2
is independently a noninterfering substituent;
L is a linker;
n is 0 or 1; and
Ar′ is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.
The invention is directed to methods of treating inflammation or proliferative conditions using these compounds. The invention is also directed to treating conditions associated with cardiac failure using the invention compounds.
REFERENCES:
patent: 3971783 (1976-07-01), Barnish et al.
patent: 4435003 (1984-03-01), Fletcher
patent: 4480096 (1984-10-01), Fletcher
patent: 4480883 (1984-11-01), Young
patent: 4557998 (1985-12-01), Washburn et al.
patent: 4695575 (1987-09-01), Janssens et al.
patent: 5430148 (1995-07-01), Webber et al.
patent: 5439895 (1995-08-01), Lee et al.
patent: 5475001 (1995-12-01), Barker
patent: 5480883 (1996-01-01),
Chakravarty Sarvajit
Dugar Sundeep
Lewicki John A.
Liu David Y.
Perumattam John J.
Liu Hong
Morrison & Foerster / LLP
Scios Inc.
Shah Mukund J.
LandOfFree
Quinazoline derivatives as medicaments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazoline derivatives as medicaments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline derivatives as medicaments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2993422